IAG Team to Attend Biotech Week in San Francisco, USA, 4-11 January 2019
IAGs’ bio-partnering and management team will be attending biotech week in San Francisco. IAG’s CEO, Dr. Olga Kubassova will attend JP Morgan meeting and Head of Therapeutic Innovation, Dr. Diana Roettger will be attending Biotech Showcase and satellite events in San Francisco, USA, from January 5-10.
IAG partners with biotechnology and pharmaceutical companies and supports clinical research programs with its scientific, operational and technological expertise. IAG Bio-Partnering division is an independent investment division of IAG that works to build a diversified investment portfolio of innovative life science companies at various stages of clinical development.
The scope of discussions for this conference include:
– Development of clinical stage assets
– IP acquisition from the academic partners and biotech companies
– Investment partnerships
– Strategic collaborations
Given the increasing need for collaboration in therapy development, Dr. Kubassova and Dr. Roettger will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies. To find out more about IAG Bio-Partnering services or to schedule a meeting during biotech week of 2019 please send an email to firstname.lastname@example.org
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com